KOHNO MASAYUKI 河野雅之

… Alternative Names

KOHNO Masayuki 河野雅之

Less

Researcher Number	00437203
Other IDs
Affiliation (based on the past Project Information) *help	2016 – 2017: 京都大学, 医学研究科, 特定講師 2016 – 2017: 京都大学, 大学院医学研究科, 特定講師 2015: 京都大学, 医学(系)研究科(研究院), 講師 2013: 京都大学, 大学院医学研究科, 助教 2010: 京都大学, 医学研究科, 客員研究員 … More 2010: Kyoto University, 大学院・医学研究科, 客員研究員 2007 – 2009: Kyoto University, 医学研究科, 助教 2008: Kyoto University, 大学院・医学研究科, 助教 Less
Review Section/Research Field	Principal Investigator Applied pharmacology / Drug development chemistry Except Principal Investigator Medical pharmacy / Tumor therapeutics / Clinical oncology
Keywords	Principal Investigator 低侵襲化 / 加齢黄斑変性 / 血管新生 / フィトケミカル / 網膜変性 / DDS / 局所投与 / 分子標的 / ペプチド創薬 / 医薬分子設計 … More / 医療・福祉 / 薬学 / 核酸 / 間質性肺炎 / siRNA医薬 / siRNA / 薬物治療学 … More Except Principal Investigator 難治性癌 / ハイブリッドペプチド / ペプチド創薬 / 分子標的治療 / ドラックデリバリー / 経口製剤 / ドラッグデリバリー / ペプチド / 薬物動態学 / 治療抵抗性 Less

Improvement of oral delivery of hybrid peptide using absorption enhancer
- Principal Investigator
  
  Gaowa Arong
- Project Period (FY)
  2016 – 2017
- Research Category
  
  Grant-in-Aid for Young Scientists (B)
- Research Field
  
  Medical pharmacy
- Research Institution
  Mie University
  Kyoto University
Exploratory research of new drugs for age-related macular degeneration decreasing treatment cost and invasivenessPrincipal Investigator
- Principal Investigator
  
  Kohno Masayuki
- Project Period (FY)
  2015 – 2017
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Research Field
  
  Applied pharmacology
- Research Institution
  Kyoto University
Study on new strategy of glioblastoma treatment by molecular targeted anti-cancer hybrid peptide
- Principal Investigator
  
  Kawakami Koji
- Project Period (FY)
  2014 – 2016
- Research Category
  
  Grant-in-Aid for Scientific Research (B)
- Research Field
  
  Tumor therapeutics
- Research Institution
  Kyoto University
Development of cancer treatment by molecular targeted anti-cancer hybrid peptide against refractory cancers which are resistant to cancer chemotherapy
- Principal Investigator
  
  KAWAKAMI Koji
- Project Period (FY)
  2011 – 2013
- Research Category
  
  Grant-in-Aid for Young Scientists (A)
- Research Field
  
  Clinical oncology
- Research Institution
  Kyoto University
Basic research of new local treatment for inflammatory diseases using molecular-targeting chimera peptidePrincipal Investigator
- Principal Investigator
  
  KOHNO Masayuki
- Project Period (FY)
  2009 – 2010
- Research Category
  
  Grant-in-Aid for Young Scientists (B)
- Research Field
  
  Drug development chemistry
- Research Institution
  Kyoto University
Basic research of cocktail-siRNA treatment for interstitial pneumonia using intratracheal sprayPrincipal Investigator
- Principal Investigator
  
  KOHNO Masayuki
- Project Period (FY)
  2007 – 2009
- Research Category
  
  Grant-in-Aid for Young Scientists (B)
- Research Field
  
  Applied pharmacology
- Research Institution
  Kyoto University

All 2018 2017 2014 2013 2012 2011 2010 2009 Other

All Journal Article Presentation Patent

[Journal Article] Bile acid as an effective absorption enhancer for oral delivery of epidermal growth factor receptor targeted hybrid peptide2018
- Author(s)
  Gaowa, A., Horibe, T., Kohno, M., Kawakami, K
- Journal Title
  
  J Pharm Sci
  
  Volume: 107 Issue: 5 Pages: 1322-1329
- DOI
  10.1016/j.xphs.2017.12.012
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-16K18937
[Journal Article] Development of molecular targeted anti-cancer hybrid peptide for novel cancer therapy2017
- Author(s)
  堀部　智久、河野　雅之、瀬戸　佳穂里、阿栄高娃、川上　浩司
- Journal Title
  
  生化学
  
  Volume: 89 Issue: 1 Pages: 31-38
- DOI
  10.14952/SEIKAGAKU.2017.890031
- ISSN
  0037-1017
- Year and Date
  2017-02-25
- Language
  Japanese
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-16K18937
[Journal Article] The membrane-lytic peptide K8L9 and melittin enter cancer cells via receptor endocytosis following subcytotoxic exposure.2014
- Author(s)
  Kohno M, (他3名), and Kawakami K.
- Journal Title
  
  Chemistry & Biology
  
  Volume: 21 Issue: 11 Pages: 1-11
- DOI
  10.1016/j.chembiol.2014.09.008
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-26290052
[Journal Article] Localization of the anti-cancer peptide EGFR-lytic hybrid peptide in human pancreatic cancer BxPC-3 cells by immunocytochemistry2013
- Author(s)
  Ohara, K., Kohno, M., and Kawakami, K
- Journal Title
  
  J. Peptide Sci.
  
  Volume: 19 Issue: 8 Pages: 511-515
- DOI
  10.1002/psc.2529
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-23680089
[Journal Article] Entry of a cationic lytic-type peptide into the cytosol via endocytosis-dependent and–independent pathways in human glioma U251 cells2013
- Author(s)
  Ohara, K., Kohno, M., Hamada, T., and Kawakami, K
- Journal Title
  
  Peptides
  
  Volume: 50 Pages: 28-35
- DOI
  10.1016/j.peptides.2013.09.015
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-23680089, KAKENHI-PROJECT-23740316, KAKENHI-PUBLICLY-25104510
[Journal Article] Her2 targeted hybrid peptide that blocks her2 tyrosine kinase disintegrates cancer cell membrane and inhibits tumor growth in vivo2013
- Author(s)
  Kawamoto, M., Horibe, T., Kohno, M., and Kawakami, K
- Journal Title
  
  Mol Cancer Ther
  
  Volume: 12 Issue: 4 Pages: 384-393
- DOI
  10.1158/1535-7163.mct-12-0357
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-23680089
[Journal Article] Immunogenicity and toxicity of transferring receptor-targeted hybrid peptide as a potent anticancer agent2013
- Author(s)
  Kawamoto, M., Kohno, M., Horibe, T., and Kawakami, K
- Journal Title
  
  Cancer Chemother Pharmacol
  
  Volume: 71 Issue: 3 Pages: 799-807
- DOI
  10.1007/s00280-013-2074-4
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-23680089
[Journal Article] Targeting interleukin-4 receptor alpha with hybrid peptide for effective cancer therapy2012
- Author(s)
  Yang, L., Horibe, T., Kohno, M., Haramoto, M., Ohara, K., Puri, R., and Kawakami, K
- Journal Title
  
  Mol Can Ther
  
  Volume: 11 Issue: 1 Pages: 235-243
- DOI
  10.1158/1535-7163.mct-11-0363
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-23680089
[Journal Article] Semaphorin 3A-lytic hybrid peptide binding to neuropillin-1 as a novel anti-cancer agent in pancreatic cancer2011
- Author(s)
  Ueyama, H., Horibe, T., Nakajima, O., Ohara, K., Kohno, M., and Kawakami, K
- Journal Title
  
  Biochem. Biophys. Res. Commun
  
  Volume: 414 Issue: 1 Pages: 60-66
- DOI
  10.1016/j.bbrc.2011.09.021
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-23680089
[Journal Article] A novel Transferrin-receptor-targeted hybrid peptide permeates the cancer cell membrane to induce rapid killing of cancer cells2011
- Author(s)
  Kawamoto, M., Horibe, T., Kohno, M., and Kawakami, K
- Journal Title
  
  BMC cancer
  
  Volume: 11 Issue: 1 Pages: 359-359
- DOI
  10.1186/1471-2407-11-359
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-23680089
[Journal Article] A novel hybrid peptide targeting EGFR-expressing cancers.2011
- Author(s)
  Kohno M, Horibe T, Haramoto M, Yano Y, Ohara K, Nakajima O, Matsuzaki K, Kawakami K.
- Journal Title
  
  Eur J Cancer. 47
  
  Pages: 773-83
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-21790111
[Journal Article] A novel hybrid peptide targeting EGFR-expressing cancers2011
- Author(s)
  河野雅之, (他7名)
- Journal Title
  
  European Journal of Cancer
  
  Volume: 47 Pages: 773-783
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-21790111
[Journal Article] Aerosolized budesonide attenuates lung fibrosis with minimal adverse effects
- Author(s)
  Kohno M, Haramoto M, Nakajima O, Yang L, Hinotsu S, Yokohira M, Imaida K, Kawakami K.
- Journal Title
  
  Eur Respir J (現在論文投稿中)
- Data Source
  KAKENHI-PROJECT-19790386
[Patent] 網膜変性疾患抑制剤2017
- Inventor(s)
  川上浩司、河野雅之、武蔵国弘
- Industrial Property Rights Holder
  京都大学
- Industrial Property Rights Type
  特許
- Industrial Property Number
  2017-237268
- Filing Date
  2017
- Data Source
  KAKENHI-PROJECT-15K08587
[Presentation] Improvement of oral delivery of EGFR-targeted hybrid peptide by combination with bile acid.2017
- Author(s)
  Gaowa. A., Horibe, T., Kohno, M., and Kawakami, K.
- Organizer
  The 12th Australian Peptide Conference
- Data Source
  KAKENHI-PROJECT-16K18937
[Presentation] Novel Her2-targeted hybrid peptide that disintegrates cancer cell membrane and inhibits tumor growth in vivo2013
- Author(s)
  Horibe, T., Kawamoto, M., Kohno, M., and Kawakami, K
- Organizer
  第72回日本癌学会学術集会
- Place of Presentation
  パシフィコ横浜
- Data Source
  KAKENHI-PROJECT-23680089
[Presentation] 抗癌ペプチドLyticの細胞における作用機序に関する研究2012
- Author(s)
  大原弘路、河野雅之、川上浩司
- Organizer
  第49回ペプチド討論会
- Place of Presentation
  鹿児島県民交流センター
- Data Source
  KAKENHI-PROJECT-23680089
[Presentation] Anti-leukemic activity of hybrid Antp-TPR peptide targeting Hsp902011
- Author(s)
  Horibe, T., Kawamoto, M., Kohno, M., and Kawakami, K
- Organizer
  第70回日本癌学会学術総会
- Place of Presentation
  名古屋国際会議場
- Data Source
  KAKENHI-PROJECT-23680089
[Presentation] Mechanism of cancer cell death by hybrid Antp-TPR peptide targeting Hsp902011
- Author(s)
  Horibe, T., Kohno, M., Haramoto, M., Ohara, K., and Kawakami, K
- Organizer
  第84回日本生化学会大会
- Place of Presentation
  京都国際会館
- Data Source
  KAKENHI-PROJECT-23680089
[Presentation] Enhancement of anticancer activity by the single amino acid conversion of EGFR-binding peptide2011
- Author(s)
  Tada, N., Horibe, T., Haramoto, M., Ohara, K., Kohno, M., and Kawakami, K
- Organizer
  第84回日本生化学会大会
- Place of Presentation
  京都国際会館
- Data Source
  KAKENHI-PROJECT-23680089
[Presentation] A novel EGFR-targeted hybrid peptide can overcome the resistance of cancer cells to tyrosine kinase inhibitors.2010
- Author(s)
  Masayuki Kohno, Tomohisa Horibe, Yoshiaki Yano, Katsumi Matsuzaki, Koji Kawakami.
- Organizer
  第69回日本癌学会学術総会
- Place of Presentation
  大阪国際会議場
- Year and Date
  2010-09-23
- Data Source
  KAKENHI-PROJECT-21790111
[Presentation] DESIGN OF A NOVEL EGFR-TARGETED HYBRID-PEPTIDE AND CHARACTERIZATION OF ITS CYTOTOXIC MECHANISM IN CANCER CELL2009
- Author(s)
  河野雅之
- Organizer
  第46ペプチド討論会
- Place of Presentation
  北九州国際会議場
- Year and Date
  2009-11-05
- Data Source
  KAKENHI-PROJECT-21790111

1. HORIBE Tomohisa (20467468)

# of Collaborated Projects: 5 results

# of Collaborated Products: 13 results
2. KAWAKAMI Koji (70422318)

# of Collaborated Projects: 3 results

# of Collaborated Products: 13 results
3. ARONGGAOWA (50643805)

# of Collaborated Projects: 2 results

# of Collaborated Products: 2 results
4. KURIHARA RYOUSUKE (20713233)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
5. SETO KAHORI (20737019)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
6. MUSASHI Kunihiro

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
7. OKUNO Yasushi

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
8. IKEDA Hanako

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
9. SEHARA Atsuko

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
10. IIDA Atsuo

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results

KOHNO MASAYUKI 河野 雅之

KOHNO Masayuki 河野 雅之

Research Projects

Research Products

Co-Researchers

Improvement of oral delivery of hybrid peptide using absorption enhancer

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

Exploratory research of new drugs for age-related macular degeneration decreasing treatment cost and invasivenessPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

Study on new strategy of glioblastoma treatment by molecular targeted anti-cancer hybrid peptide

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

Development of cancer treatment by molecular targeted anti-cancer hybrid peptide against refractory cancers which are resistant to cancer chemotherapy

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

Basic research of new local treatment for inflammatory diseases using molecular-targeting chimera peptidePrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

Basic research of cocktail-siRNA treatment for interstitial pneumonia using intratracheal sprayPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

[Journal Article] Bile acid as an effective absorption enhancer for oral delivery of epidermal growth factor receptor targeted hybrid peptide2018

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Development of molecular targeted anti-cancer hybrid peptide for novel cancer therapy2017

Author(s)

Journal Title

DOI

ISSN

Year and Date

Language

Data Source

[Journal Article] The membrane-lytic peptide K8L9 and melittin enter cancer cells via receptor endocytosis following subcytotoxic exposure.2014

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Localization of the anti-cancer peptide EGFR-lytic hybrid peptide in human pancreatic cancer BxPC-3 cells by immunocytochemistry2013

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Entry of a cationic lytic-type peptide into the cytosol via endocytosis-dependent and–independent pathways in human glioma U251 cells2013

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Her2 targeted hybrid peptide that blocks her2 tyrosine kinase disintegrates cancer cell membrane and inhibits tumor growth in vivo2013

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Immunogenicity and toxicity of transferring receptor-targeted hybrid peptide as a potent anticancer agent2013

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Targeting interleukin-4 receptor alpha with hybrid peptide for effective cancer therapy2012

KOHNO MASAYUKI 河野雅之

KOHNO Masayuki 河野雅之